Anxiety Depression DisorderTAD-GENDGFNCT06112457
Anxiety and Depression Among Gendarmes Posted to French Guiana
An observational study of Anxiety Depression Disorder, run by Direction Centrale du Service de Santé des Armées at 1 site in French Guiana.
Trial summary
This is a mixed-method, single-center study involving two concurrent phases: a quantitative phase with an anonymous self-administered questionnaires, and a qualitative phase with individual contextual interviews and a focus group. Read more about this study
- Who is it for?
- Ages 18 to 65 yearsHealthy volunteers can take part
- Conditions the study is for
- Anxiety Depression Disorder
- What is being tested?
- Survey
- How many people
- 600 participants
- Where
- 1 siteFrench Guiana
- Study dates
- Nov 2023to Nov 2024
- How long will I take part?
- 1 Month
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: healthy volunteer
Who may be able to join
- Gendarme in active position
- Age over 18
- Assignment in French Guiana for more than 6 months at the time of the study
- Not opting for study participation
Who cannot join
- Previously diagnosed psychiatric condition
- People with a reading/writing disability in the French language
- Major incapacity
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Anxiety and Depression Among Gendarmes Posted to French Guiana (TAD-GENDGF)
This is a mixed-method, single-center study involving two concurrent phases: a quantitative phase with an anonymous self-administered questionnaires, and a qualitative phase with individual contextual interviews and a focus group. The hypothesis underlying this study is that isolated postings are a risk factor for anxiety-depressive disorders. The aim of this study is to provide new information to help propose targeted prevention and health promotion measures.
- Conditions
- Anxiety Depression Disorder
- Being tested
- Survey
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
SurveyOther
Anonymous self-administered questionnaire
What is being measured
The primary outcome is the main question the study is designed to answer.
Prevalence of anxiety-depressive disorders according to posting site.
Comparison of the prevalence of anxiety-depressive disorders among gendarmes posted to French Guiana according to their posting site.
Measured: Through study completion (6 months)
Secondary outcomes (1)
Factors associated with the presence of an anxiety-depressive disorder
Evaluate factors associated with the presence of an anxiety-depressive disorder, both overall and by type of disorder
Measured: Through study completion (6 months)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Nov 2023
- Study startNov 2023 (estimated)
- Primary completionOct 2024 (estimated)
- Study completionNov 2024 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Anxiety Depression DisorderStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Ecologic or community
- Time perspective
- Prospective
- Enrolment
- 600 participants (estimated)
- Target duration
- 1 Month
Sponsor and investigators
- Lead sponsor
- Direction Centrale du Service de Santé des Armées
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06112457
- Sponsor's protocol ID
- 2022PPRC07
- Other IDs
- 2023-100889-36, 2023
- Acronym
- TAD-GENDGF
- Status last verified
- Oct 2023
- First submitted
- 26 Oct 2023
- Last updated
- 1 Nov 2023
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 1 Nov 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Anxiety and Depression Among Gendarmes Posted to French Guiana (TAD-GENDGF)
- ClinicalTrials.gov ID
- NCT06112457
- Acronym / sponsor ID
- TAD-GENDGF / 2022PPRC07
- Conditions
- Anxiety Depression Disorder
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 600 participants (estimated)
- Lead sponsor
- Direction Centrale du Service de Santé des ArméesUniversity, hospital or other
- Study start
- Nov 2023 (estimated)
- Primary completion
- Oct 2024 (estimated)
- Study completion
- Nov 2024 (estimated)
- First posted
- 1 Nov 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a mixed-method, single-center study involving two concurrent phases: a quantitative phase with an anonymous self-administered questionnaires, and a qualitative phase with individual contextual interviews and a focus group. The hypothesis underlying this study is that isolated postings are a risk factor for anxiety-depressive disorders. The aim of this study is to provide new information to help propose targeted prevention and health promotion measures.
Study design
- Observational model
- Ecologic or community
- Time perspective
- Prospective
- Target follow-up
- 1 Month
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- healthy volunteer
Key inclusion criteria (4 listed)
- Gendarme in active position
- Age over 18
- Assignment in French Guiana for more than 6 months at the time of the study
- Not opting for study participation
Key exclusion criteria (3 listed)
- Previously diagnosed psychiatric condition
- People with a reading/writing disability in the French language
- Major incapacity
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| SurveyAnonymous self-administered questionnaire | Other | – |
Primary outcome
Prevalence of anxiety-depressive disorders according to posting site.
Time frame: Through study completion (6 months)
Comparison of the prevalence of anxiety-depressive disorders among gendarmes posted to French Guiana according to their posting site.
1 secondary outcome
Factors associated with the presence of an anxiety-depressive disorder
Time frame: Through study completion (6 months)
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 Nov 2023.
- Individual participant dataSharing planned: Undecided
Related trials for Anxiety Depression Disorder
Recruiting
Unified Protocol in Penitentiary Facilities
Depression Disorders, Anxiety
Not yet recruiting
Preventive and Personalized Digital Emotion Regulation Skills Intervention to Reduce Depression and Anxiety in Youths With Adverse Childhood Experiences
Adverse Childhood Experience, Depression / Major Depressive Disorder
Not yet recruitingObservational study
Functional Impact of Psychological Symptoms in Patients With Superior Semicircular Canal Dehiscence Syndrome (SSCD): a National Cross-sectional Study
Superior Semicircular Canal Dehiscence
Recruiting
Trial Phase: Syndemic Adapted Medly Uganda
Mental Health
Recruiting
Cultural Adaptation of an Online Parenting Intervention to Reduce the Risk of Depression and Anxiety in Adolescents
Risk of Depression and Anxiety
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Anxiety Depression Disorder, run by Direction Centrale du Service de Santé des Armées at 1 site in French Guiana.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 1 Nov 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in French Guiana. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact DIA (0594395983, aissata.dia@intradef.gouv.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Prevalence of anxiety-depressive disorders according to posting site. (time frame: Through study completion (6 months)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Nov 2023.